Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
Improvements were participant-led, using real-time glucose readings to guide everyday decisions Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population ABBOTT PARK, Ill. March 12, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). About 63 million people worldwide rely on insulin to manage Type 2 diabetes , but real-world studies show only 18%–30% of those using basal insulin are reaching their HbA1c goals. This gap contributes to an estimated $217
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementPR Newswire
- Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks [Yahoo! Finance]Yahoo! Finance
- Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementPR Newswire
- 3 Analyst-Approved Stocks With Fat Yields That Could Rally 27% or More [Yahoo! Finance]Yahoo! Finance
- Abbott Laboratories (ABT) had its price target lowered by Citigroup Inc. from $140.00 to $136.00. They now have a "buy" rating on the stock.MarketBeat
ABT
Earnings
- 1/22/26 - In-Line
ABT
Sec Filings
- 3/9/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- ABT's page on the SEC website